Darbepoetin Alfa In Polysorbat
Average cost per year*
Average cost per beneficiary*
This medication is used to treat anemia (low red blood cell count) in people with long-term serious kidney disease (chronic kidney failure) and people receiving chemotherapy for some types of cancer (cancer that does not involve the bone marrow or blood cells). Darbepoetin alfa also helps to reduce the need for blood transfusions. It works by signaling the bone marrow to make more red blood cells. This medication is very similar to the natural substance in your body (erythropoietin) that prevents anemia. NOTE: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
*Origin of the terms and chart data used within this page: https://data.cms.gov/
Yes, Aranesp is covered by Medicare.
In 2021, the average cost per dose of Aranesp was $2,298.24.
The average dose of Aranesp received per year is 28,350 units
5,130 Medicare beneficiaries received Aranesp in 2021, which was a -0.11% from 2020
There were 22,268 claims made by Medicare beneficiaries, which is a -0.11% from 2020
The average spending amount per claim in 2021 was $2,277.53
The average Medicare spending per beneficiary amount for Aranesp was $9,886.18
Amgen received $50,716,091.04
The total amount spent on Aranesp by Medicare is $50,716,091.04
Short Term Medical Insurance
Limited Fixed Indemnity Plans